CAT and metabolic dysfunction-associated steatotic liver disease: LFABP prevents non-alcoholic fatty liver disease (NAFLD) development by shuttling long-chain fatty acids towards the mitochondria for β-oxidation and possibly by acting as an antioxidant when intracellular antioxidants (CAT, SOD, GPx) are insufficient [77].